Dexamethasone intravitreal implant for treatment of patients with recalcitrant macular edema resulting from Irvine-Gass syndrome

Investigative Ophthalmology and Visual Science

Volumn 54, Issue 5, 2013, Pages 3320-3324

  Medeiros, Marco Dutra ^a   Navarro, Rafael ^a   Garcia Arumí, José ^a,b   Mateo, Carlos ^a   Corcóstegui, Borja ^a  

^a Ocular Microsurgery Institute   (Spain)

^b HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

Irvine Gass syndrome; Ozurdex; Refractory macular edema

Indexed keywords

DEXAMETHASONE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DRUG IMPLANT; FEMALE; FOLLOW UP; FOVEAL THICKNESS; GENERAL CONDITION IMPROVEMENT; HUMAN; IRVINE GASS SYNDROME; MALE; MEDICAL RECORD REVIEW; OCULOPLETHYSMOGRAPHY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RETINA FLUORESCEIN ANGIOGRAPHY; RETINA FOVEA; RETINA MACULA EDEMA; SINGLE DRUG DOSE; SPECTRAL DOMAIN OPTICAL COHERENCE TOMOGRAPHY; SYNDROME; VISUAL ACUITY;

IRVINE-GASS SYNDROME; OZURDEX; REFRACTORY MACULAR EDEMA;

ADULT; AGED; AGED, 80 AND OVER; DEXAMETHASONE; DRUG IMPLANTS; FEMALE; FLUORESCEIN ANGIOGRAPHY; GLUCOCORTICOIDS; HUMANS; INTRAVITREAL INJECTIONS; MACULAR EDEMA; MALE; MIDDLE AGED; PSEUDOPHAKIA; RETROSPECTIVE STUDIES; TOMOGRAPHY, OPTICAL COHERENCE; TONOMETRY, OCULAR; TREATMENT OUTCOME; VISUAL ACUITY; VITREOUS BODY;

EID: 84877670599     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.12-11463     Document Type: Article

References (34)

1. Irvine SR. A newly defined vitreous syndrome following cataract surgery. Am J Ophthalmol. 1953;36:599-619.
2. Gass JDM, Norton EWD. Fluorescein studies of patients with macular edema and papilledema following cataract extraction. Trans Am Ophthalmol Soc. 1966;64:232-249.
3. Gass JDM, Norton EWD. Cystoid macular edema and papilledema following cataract extraction. Arch Ophthalmol. 1966;76:646-661.
4. Flach AJ. The incidence, pathogenesis and treatment of cystoid macular edema following cataract surgery. Trans Am Ophthalmol Soc. 1998;96:557-634.
5. Yonekawa Y, Kim IK. Pseudophakic cystoid macular edema. Curr Opin Ophthalmol. 2012;23:26-32.
6. Benitah NR, Arroyo JG. Pseudophakic cystoid macular edema. Int Ophthalmol Clin. 2010;50:139-153.
7. Shelsta HN, Jampol LM. Pharmacologic therapy of pseudophakic cystoid macular edema: 2010 update. Retina. 2011;31: 4-12.
8. Sivaprasad S, Bunce C, Wormland R. Non-steroidal anti inflammatory agents for cystoid macular edema following cataract surgery: a systematic review. Br J Ophthalmol. 2005; 89:1420-1422.
9. Abraham SM, Lawrence T, Kleiman A, et al. Antiinflammatory effects of dexamethasone are partly dependent on induction of dual specificity phosphatase 1. J Exp Med. 2006;203:1883-1889.
10. Barnes PJ. Corticosteroid effects on cell signalling. Eur Respir J. 2006;27:413-426.
11. Saklatvala J. Glucocorticoids: do we know how they work? Arthritis Res. 2002;4:146-150.
12. Walker BR. Glucocorticoids and cardiovascular disease. Eur J Endocrinol. 2007;157:545-559.
13. Nauck M, Karakiulakis G, Perruchoud AP, et al. Corticosteroids inhibit the expression of the vascular endothelial growth factor gene in human vascular smooth muscle cells. Eur J Pharmacol. 1998;341:309-315.
14. Haller JA, Bandello F, Belfort R Jr, et al.; Ozurdex GENEVA Study Group. Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. Ophthalmology. 2010;117:1134-1146.
15. Haller JA, Kuppermann BD, Blumenkranz MS, et al.; Dexamethasone DDS Phase II Study Group. Randomized controlled trial of an intravitreous dexamethasone drug delivery system in patients with diabetic macular edema. Arch Ophthalmol. 2010;128:289-296.
16. Boyer DS, Faber D, Gupta S, et al.; Ozurdex Champlain Study Group. Dexamethasone intravitreal implant for treatment of diabetic macular edema in vitrectomized patients. Retina. 2011;31:915-923.
17. Chang-Lin JE, Attar M, Acheampong AA, et al. Pharmacokinetics and pharmacodynamics of a sustained-release dexamethasone intravitreal implant. Invest Ophthalmol Vis Sci. 2011;52: 80-86.
18. Saraiya NV, Goldstein DA. Dexamethasone for ocular inflammation. Expert Opin Pharmacother. 2011;12:1127-1131.
19. Chang-Lin JE, Burke JA, Peng Q, et al. Pharmacokinetics of a sustained-release dexamethasone intravitreal implant in vitrectomized and nonvitrectomized eyes. Invest Ophthalmol Vis Sci. 2011;52:4605-4609.
20. Lowder C, Belfort R Jr, Lightman S, et al.; Ozurdex HURON Study Group. Dexamethasone intravitreal implant for noninfectious intermediate or posterior uveitis. Arch Ophthalmol. 2011;129:545-553.
21. Kodama M, Numaga J, Yoshida A. Effects of a new dexamethasone-delivery system (Surodex) on experimental intraocular inflammation models. Graefes Arch Clin Exp Ophthalmol. 2003;241:927-933.
22. Sivaprasad S, McCluskey P, Lightman S. Intravitreal steroids in the management of macular oedema. Acta Ophthalmol Scand. 2006;84:722-733.
23. Fung WE. Vitrectomy for chronic aphakic cystoid macular edema: results of a national, collaborative, prospective, randomized investigation. Ophthalmology. 1985;92:1102-1111.
24. Benhamou N, Massin P, Haouchine B. Intravitreal triamcinolone for refractory pseudophakic macular edema. Am J Ophthalmol. 2003;135:246-249.
25. Conway MD, Canakis C, Livir-Rallatos C. Intravitreal triamcinolone acetonide for refractory chronic pseudophakic cystoids macular edema. J Cataract Refract Surg. 2003;29:27-33.
26. Deuter CM, Gelisken F, Stubiger N. Successful treatment of chronic pseudophakic macular edema (Irvine-Gass syndrome) with interferon alpha: a report of three cases. Ocul Immunol Inflamm. 2011;19:216-218.
27. Wu L, Arevalo JF, Hernandez-Bogantes E. Intravitreal infliximab for refractory pseudophakic cystoid macular edema: results of the Pan-American Collaborative Retina Study Group. Int Ophthalmol. 2012;32:235-243.
28. Steinert RF, Wasson PJ. Neodymium: YAG laser anterior vitreolysis for Irvine-Gass cystoid macular edema. J Cataract Refract Surg. 1989;15:304-307.
29. Spitzer MS, Ziemssen F, Yoeruek E. Efficacy of intravitreal bevacizumab in treating postoperative pseudophakic cystoids macular edema. J Cataract Refract Surg. 2008;34:70-75.
30. Warren KA, Bahrani H, Fox JE. NSAIDs in combination therapy for the treatment of chronic pseudophakic cystoid macular edema. Retina. 2010;30:260-266.
31. London NJ, Chiang A, Haller JA. The dexamethasone drug delivery system: indications and evidence. Adv Ther. 2011;28: 351-366.
32. Williams GA, Haller JA, Kuppermann BD. Dexamethasone posterior-segment drug delivery system in the treatment of macular edema resulting from uveitis or Irvine-Gass syndrome. Am J Ophthalmol. 2009;147:1048-1054.
33. Khurana R. Ozurdex for combined pseudophakic cystoid macular edema and diabetic macular edema after cataract surgery. US NIH. 2012. Available at: http://clinicaltrials.gov/ct2/show/NCT01284478. Accessed November 21, 2012.
34. Diabetic Retinopathy Clinical Research Network (DRCR.net), Beck RW, Edwards AR, et al. Three-year follow-up of a randomized trial comparing focal/grid photocoagulation and intravitreal triamcinolone for diabetic macular edema. Arch Ophthalmol. 2009;127:245-251.